340B Report: Stakeholders Say Trump’s Renewed Push to Move 340B to CMS, Increase Program Funding Could Signal New Focus on Program

The Trump administration’s FY 2027 budget proposal seeks to move 340B program oversight from HRSA to CMS, while significantly increasing its funding. This move could signal a major shift in federal drug pricing policy, reports 340B Report. The proposed reorganization, which includes a 68% funding increase to $20.5 million for the Office of Pharmacy Affairs […]

ACH Statement on Proposed 340B Funding Increase

Advocates for Community Health (ACH) is encouraged by the proposed HHS funding increase for the 340B Drug Pricing Program. Increased funding from $12.2 million to $20.5 million enables greater transparency and accountability across participating providers, and ensures manufacturers aren’t unduly restricting covered entities. ACH has advocated for increased funding for this very reason and looks […]

Axios: More upheaval in discount drug program

Axios reports that the federal 340B drug pricing program—an $81 billion lifeline for safety-net providers—is facing mounting pressure from major pharmaceutical companies and new federal policy shifts. Stephanie Krenrich, who leads policy and government affairs at Advocates for Community Health, was recently interviewed for the article by Maya Goldman. Drugmakers like Eli Lilly and Novo […]

340B Report: Provider Groups Defend 340B

A recent 340B Report article from Luke Zarzecki highlights the ongoing efforts in Washington, D.C., to preserve the 340B drug pricing program for health centers and other safety-net providers. While some lawmakers are exploring 340B reforms, including rebate models and the proposed 340B ACCESS Act, the reality is that 340B is a vital lifeline. 340B […]

Protecting What Matters: ACH Launches 340B Learning Collaborative at a Critical Moment

At a time when the 340B program is under increasing pressure, Advocates for Community Health (ACH) is stepping forward to help guide the path ahead. Last week, Advocates for Community Health (ACH) officially kicked off its 340B Learning Collaborative, bringing together health center 19 leaders from 15 states for a focused, solutions-driven effort to strengthen […]

Inside the Deal Room: What Federal Policy Really Means for CHCs

In this episode of Community Health Centers Unfiltered, Advocates for Community Health goes beyond the headlines to explore how federal health policy is actually made — and what that process means for the stability and sustainability of community health centers (CHCs). Co-Host Margaret French of Venn Strategies is joined by Debbie Curtis and Rodney Whitlock […]

Leading the Way Forward: What the ACH Annual Meeting Revealed About the Future of Community Health Centers

The federal healthcare landscape is shifting rapidly, but community health centers (CHCs)  continue to demonstrate how community-driven primary care can meet the moment. That was the clear message from Advocates for Community Health’s 5th Annual Member Meeting, where health center leaders, federal officials, and policymakers gathered in Washington to chart the next chapter in health […]

Modern Healthcare: Novo Nordisk, Eli Lilly tighten 340B oversight as providers fume

ACH’s SVP of Policy & Government Affairs Stephanie Krenrich was featured in this article today on the 340B Rebate Model from Bridget Early at Modern Healthcare: “Drugmakers are upping their demands for transparency in the 340B Drug Pricing Program by imposing new requirements that have sparked ire among safety-net providers,”  reports Bridget Early. “Novo Nordisk […]

Copyright © 2026 Advocates for Community Health Privacy Policy